Digipath
CHM Cannabis
Home > Boards > US Listed > Biotechs >

GT Biopharma Inc. (GTBP)

GTBP RSS Feed
Add GTBP Price Alert      Hide Sticky   Hide Intro
Moderator: 236T568, CashBowski
Search This Board: 
Last Post: 12/12/2018 4:27:44 PM - Followers: 171 - Board type: Free - Posts Today: 0

OTCQB: GTBP







The Scourge of Cancer

Cancer is the second leading cause of death globally, and responsible for 8.8 million deaths annually.  The economic impact of cancer is increasing. The total annual economic cost of cancer in 2015 was estimated at approximately US$ 2.5 trillion.  Immuno Oncology sits on the leading edge of cancer treatment and research.  In terms of effectiveness it promises to drastically outpace all previous forms of conventional cancer therapy.  Some estimate the Immuno Oncology market at $US 40 Billon and growing.



What is Immuno Oncology?

Immuno Oncology is treatment that recruits and supercharges a person's own immune system components to fight cancer. This can take various forms: the immune system can be stimulated to work harder or smarter in attacking cancer cells, immune system components can be supplied such as man-made immune proteins that attack cancer cells in a targeted way, immune system cells can be "programmed" to only attack very specific cancer cells or even to deliver a "payload" of compounds poisonous to cancer directly and only to the malignant cells. 
 

   




Immuno Oncology Goes Beyond Drawbacks of Conventional Chemotherapy
Conventional chemotherapy poisons the patient's body with the aim of getting the cancer too. Its like spraying a powerful herbicide on your rose garden to get rid of the dandelions. Yes, the weeds will die but the roses will suffer too.

With Immuno Oncology, the cure is not worse than the disease. Many of the harsh and debilitating side effects of chemotherapy are avoided because the agents that kill the cancer are components of the human immune system itself, rather than poison, and the therapy can be precisely targeted to only attack the cancerous cells.  It is truly the next evolutionary leap in cancer treatment.   




GT Biopharma Portfolio



GTBP Therapy Pipeline Highlights

OXS-1550: Treating Lymphoma and Leukemia
When OXS-1550 binds to cancer cells, the cancer cells internalize OXS-1550, and are killed due to the action of drug’s cytotoxic diphtheria toxin payload.  OXS-1550 has demonstrated success in a Phase 1 human clinical trial in patients with relapsed/refractory B-cell lymphoma or leukemia.

The initial phase 1 study enrolled 25 patients (who) received at least a single course of therapy. The treatment at the higher doses produced objective tumor responses with one patient in continuous partial remission and the second in complete remission. Data from ongoing phase 2 expected in 2H ‘18.

OXS-3550: Treating Leukemia
The OXS-3550 IND will focus on AML, the most common form of adult leukemia with 21,000 new cases expected in 2017 alone (American Cancer Society). These patients will require frontline therapy, usually chemotherapy including cytarabine and an anthracycline, a therapy that has not changed in over 40 years.

OXS-1615 AND OXS-C3550: Treating Solid Tumors
This TetraKE is designed to kill not only the heterogeneous population of cancer cells found in solid tumors but also kill the cancer stem cells that are typically responsible for recurrences.



Other Offerings: Central Nervous System Therapies

GTP-011: Motion Sickness Treatment

GTP-011 is a 72-hour patch for which a patent application has been filed by GTP for the prevention of motion sickness, a well-known syndrome that typically involves nausea and vomiting in otherwise healthy people and that occurs upon exposure to certain types of motion.

PainBrake: Treating Neuropathic Pain 
PainBrake® is a new patented formulation of carbamazepine (Tegretol®) that enables accurate dose fractionation for the treatment of neuropathic pain.  An NIH-supported study estimated that almost 16 million Americans suffer from chronic neuropathic pain. Current drugs provide a useful degree of pain relief in only about half the patients. 

GTP-004: Treating Myasthenia Gravis
GTP-004 is a fixed-dose combination tablet for the treatment of myasthenia gravis. Myasthenia gravis is a chronic autoimmune disease of the neuromuscular junction characterized by muscle weakness. The prevalence of the disease in the United States is estimated at 14 to 20 per 100,000 population, approximately 36,000 to 60,000 cases in the U.S. 

 


GT Biopharma Executive Team: A Who's Who Of The Biotech Sector

"Look at Where Deutsche Bank’s Shawn Cross, Pfizer’s Dr. Raymond Urbanski, Chase Pharmaceutical’s Dr. Kathleen Clarence-Smith, and Barker Davis Founder Geoffrey Davis are making their bets.  Some of the biotech sector’s most affluent and influential individuals are making a move... to GT Biopharma Inc. (GTBP). This up-and-coming biotech company has a therapy pipeline that has attracted some of the industry’s most experienced leaders."




 



Company Website

GTBP Investor's Overview

GTBP News



Digipath
CHM Cannabis
GTBP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GTBP News: Current Report Filing (8-k) 11/15/2018 08:03:35 AM
GTBP News: Quarterly Report (10-q) 11/14/2018 06:16:20 AM
GTBP News: Current Report Filing (8-k) 11/01/2018 09:32:20 AM
GTBP News: Current Report Filing (8-k) 10/16/2018 04:07:21 PM
GTBP News: Current Report Filing (8-k) 10/12/2018 04:19:28 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#16460  Sticky Note GTBP CEO Shawn Cross ABRUPTLY resigns as CEO 236T568 07/25/18 01:52:51 PM
#9588  Sticky Note The topic of this board is OXIS. The CashBowski 03/31/17 11:03:34 AM
#17846   News from 6 days ago, in case anyone’s CashBowski 12/12/18 04:27:43 PM
#17845   Gold & energy options llc swanlinbar 11/20/18 03:42:35 PM
#17844   thanks who is the stock promoter? 236T568 11/20/18 01:58:59 PM
#17843   This pretty much sums up the pump article: 236T568 11/20/18 01:56:38 PM
#17842   GTBP ****Be carefull Just Got the Pump & swanlinbar 11/20/18 01:17:12 PM
#17841   GT Biopharma Inc. (OTCMKTS:GTBP): FDA Clinical Trials Clearance TPX 11/20/18 10:20:20 AM
#17840   NEWS! GT Biopharma Announces Presentation of Two Abstracts TPX 11/20/18 10:17:11 AM
#17839   Beast mode!! JustBegin 11/19/18 11:12:13 PM
#17838   GT Biopharma Nov 14 2018 PRESENTATIONS https://d1io3yog0oux5.cloudfront.n TPX 11/19/18 10:00:48 AM
#17837   Looks like we are going to start making Mindsplit 11/16/18 03:26:25 PM
#17836   buy it up!!!! Heading back up ! Fiesta11 11/16/18 11:28:07 AM
#17835   Thumbs up !!!looks great Fiesta11 11/16/18 11:22:53 AM
#17834   I picked some GTBP us at .66. This conix 11/16/18 08:48:33 AM
#17833   BUY !!!! This is looking good right about now! Fiesta11 11/15/18 10:14:27 AM
#17832   It is always educational and entertaining to watch simon wagstaff 11/15/18 09:23:54 AM
#17831   That R/S months ago sure saved us.... said Gumby525 11/15/18 08:34:06 AM
#17830   Shooooo Gumby525 11/15/18 08:31:47 AM
#17829   .05 cents , here it comes. Fibanotch 11/14/18 04:10:10 PM
#17828   Amazing. I wish I could have shorted more. simon wagstaff 11/14/18 12:41:59 PM
#17827   $0.61 and dropping! New 52 week low! 236T568 11/14/18 10:58:06 AM
#17826   TIMBER! $0.65 - New 52 week low! 236T568 11/14/18 10:54:42 AM
#17825   GTBP Massive $236 million NET LOSS 236T568 11/14/18 10:50:48 AM
#17824   Yet another ABRUPT RESIGNATION of a GTBP Director/Officer 236T568 11/14/18 10:40:25 AM
#17823   This fell off a cliff after the promo’s CashBowski 11/13/18 08:47:07 AM
#17822   Got a starter under 92 cents. Going to willlbone 11/12/18 12:25:49 PM
#17821   .05 area will be the next "split" range. Fibanotch 11/12/18 12:15:32 PM
#17820   TIMBER! $0.907 - New 52 week low! 236T568 11/12/18 11:43:37 AM
#17819   Take out those 99 cent stop loss. willlbone 11/12/18 11:42:24 AM
#17815   Time to buy more shares. This stock pmbender 11/09/18 04:28:18 PM
#17814   Ouch! $1.25 low so far today! 236T568 11/09/18 02:25:21 PM
#17813   GTBP Director & CFO ABRUPTLY resigns from GTBP 236T568 10/16/18 05:30:06 PM
#17812   This appears to be the latest promo from 236T568 10/16/18 03:34:55 PM
#17811   there typically has been no break 236T568 10/16/18 03:25:12 PM
#17810   from cash raised by diluting current stockholders 236T568 10/16/18 03:21:53 PM
#17809   My sentiments exactly. That’s why without looking at CashBowski 10/16/18 03:21:09 PM
#17808   Thanks, Cash. $2.1 Million? conix 10/16/18 03:08:47 PM
#17807   I haven’t seen one yet, but it’s generally CashBowski 10/16/18 01:18:13 PM
#17806   What promo's are going on? There usually conix 10/16/18 12:52:13 PM
#17805   Does anyone know how they’re paying for their promo’s? CashBowski 10/16/18 09:15:36 AM
#17804   GTBP - Yet another ABRUPT DIRECTOR/OFFICER RESIGNATION and 236T568 10/12/18 05:51:51 PM
#17803   GT Biopharma's Chairman and Chief Executive Officer, Raymond TPX 10/08/18 01:58:46 PM
#17802   GT Biopharma Inc (OTCMKTS:GTBP) Makes Great Strides In TPX 09/24/18 09:59:14 AM
#17801   GTBP Charts conix 09/17/18 10:56:29 AM
#17800   the key here is 236T568 09/14/18 05:21:23 PM
#17799   Damn I left out a cool mill in CashBowski 09/14/18 03:02:13 PM
#17798   $1.80 - lowest price in 2 months! 236T568 09/12/18 12:47:12 PM
#17797   Its now at about $2.6 million cash for 236T568 09/10/18 05:22:24 PM
#17796   Spending well over a million $ in a CashBowski 09/10/18 09:14:43 AM
#17795   All stocks need stock awareness, Looking for another simmons420 09/09/18 09:50:42 PM
#17794   Yeah, that headline is a little deceptive, but CashBowski 09/06/18 02:57:26 PM
PostSubject